Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Greffex Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 5 examiners and 5 art units, so the portfolio contains distinct examination environments.
LI, BAO Q is the busiest examiner, with 1 pending matter. Counsel should use matter-specific prosecution strategies and maintain separate tracking for each examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, BAO Q | 1 | 75.5% | +26.7% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
| GU, QINHUA | 1 | 76.2% | +27.1% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | — |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | LI, BAO Q | 84d overdue |
| 18025684 | ANTIBODY CONSTRUCTS TO TARGET T CELL RESPONSES TO SARS-COV PROTEIN EXPRESSING CELLS, THEIR DESIGN AND USES | XIAO, YAN | — |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | — |
| 17907571 | MAINTAINING DNA FRAGMENTS IN EUKARYOTIC CELLS, APPROACHES AND USES | GU, QINHUA | — |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1642 | 1 |
| 1672 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | LI, BAO Q | 1671 | §102 | Final Rejection | 84d overdue | Pending | May 12, 2023 |
| 18025684 | ANTIBODY CONSTRUCTS TO TARGET T CELL RESPONSES TO SARS-COV PROTEIN EXPRESSING CELLS, THEIR DESIGN AND USES | XIAO, YAN | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Mar 10, 2023 |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | 1672 | §101§102§103§112Other | Final Rejection | — | Pending | Oct 20, 2022 |
| 17907571 | MAINTAINING DNA FRAGMENTS IN EUKARYOTIC CELLS, APPROACHES AND USES | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Sep 28, 2022 |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | — | Pending | Jun 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGreffex Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Bao Q Li has the most, with 1 of Greffex Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
